C21 Investments Announces Renewed Normal Course Issuer Bid

Core Viewpoint - C21 Investments Inc. plans to initiate a normal course issuer bid (NCIB) to repurchase up to 5,898,596 common shares, approximately 5% of its outstanding shares, to enhance long-term shareholder value [1][4]. Group 1: NCIB Details - The NCIB will commence on December 9, 2025, and conclude on December 9, 2026, allowing the company to buy shares on the open market at prevailing market prices [2]. - The company may purchase up to 2% of its issued and outstanding common shares over any 30-trading day period under the NCIB [3]. - Purchases will be funded with cash on hand, and the timing and amount of purchases will depend on market conditions [2][4]. Group 2: Previous NCIB Performance - The company recently completed a previous NCIB, which allowed for the repurchase of up to 6,002,390 common shares, resulting in the cancellation of 224,000 shares at an average price of approximately C$0.20 per share [5]. Group 3: Company Overview - C21 Investments Inc. is a vertically integrated cannabis company engaged in the cultivation, processing, and distribution of cannabis and hemp-derived products in the U.S. [6]. - The company focuses on value creation through strategic acquisitions and integration of retail, manufacturing, and distribution assets, leveraging high-growth potential in branded consumer packaged goods [6].